基于含反药组合的经典名方海藻玉壶汤治疗甲状腺肿大大鼠探讨海藻不同品种与甘草配伍的生物效应与机制

海藻与甘草配伍属于中药配伍禁忌中的“十八反”反药组合范畴。但课题组在前期国家973计划课题研究中发现，在病理条件下，经典名方海藻玉壶汤中海藻和甘草反药组合并不完全表现出增毒的“相反”特性。由于古代文献和2010版《中国药典》中收载的海藻均包含两个不同品种（海蒿子、羊栖菜），是否“十八反”中记载海藻和甘草相反与海藻的品种有关？基于此，本课题拟研究病理条件下，不同品种海藻与甘草配伍的量－毒－效关系。从对下丘脑-垂体-甲状腺轴的影响探讨不同品种海藻与甘草配伍对甲状腺肿大大鼠的效应机制；从肝药酶P450相关基因及蛋白表达和肾细胞凋亡的角度探讨不同品种海藻与甘草配伍对肝肾损伤机制，为海藻甘草反药组合的临床安全、合理使用提供科学依据，也为今后进一步研究“十八反”中含多种药材基原的反药组合提供科研思路与借鉴。

Seaweed and Liquorice compatibility belongs to the category of “Eighteen antagonisms” which is an part of the controversial prohibited combinations in traditional Chinese medicine. But our early results of 973 Program showed that, under the pathology conditions, Seaweed and Liquorice anti-drug combination in the classical prescription-Haizao Yuhu decoction did not exhibit the characteristic “toxicity increasing”. In ancient literature and Chinese Pharmacopoeia 2010 Edition, seaweed contains two different varieties- Sargassum pallidum（Turn.）C.Ag. and Sargassum fusiforme（Harv.）Setch. We wonder that weather it is related to the anti-relationship between seaweed and liquorice in “Eighteen antagonisms”. So our study plans to research the dose-efficiency-toxicity relationship showed by different species of seaweed and liquorice compatibility under the pathology conditions. We will discuss the biological effect mechanism of this compatibility on goiter in rats according to the hypothalamus-pituiary-thyroid axis,and discuss its liver and kidney destroyed mechanism according to related genes and protein expression of hepatic enzyme P450 and renal cell apoptosis. These studies can provide a scientific basis for rational and safe using of Seaweed and Liquorice anti-drug combination. What’s more, it can provide thinking and reference to future research on “Eighteen antagonisms” which contains many kinds of medicinal materials.